Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Clinical and genetic features of cystic fibrosis in Japan

Abstract

Cystic fibrosis (CF) is an autosomal recessive disease caused by pathogenic variants in CF transmembrane conductance regulator (CFTR). While CF is the most common hereditary disease in Caucasians, it is rare in East Asia. In the present study, we have examined clinical features and the spectrum of CFTR variants of CF patients in Japan. Clinical data of 132 CF patients were obtained from the national epidemiological survey since 1994 and CF registry. From 2007 to 2022, 46 patients with definite CF were analyzed for CFTR variants. All exons, their boundaries, and part of promoter region of CFTR were sequenced and the presence of large deletion and duplications were examined by multiplex ligation-dependent probe amplification. CF patients in Japan were found to have chronic sinopulmonary disease (85.6%), exocrine pancreatic insufficiency (66.7%), meconium ileus (35.6%), electrolyte imbalance (21.2%), CF-associated liver disease (14.4%), and CF-related diabetes (6.1%). The median survival age was 25.0 years. The mean BMI percentile was 30.3%ile in definite CF patients aged < 18 years whose CFTR genotypes were known. In 70 CF alleles of East Asia/Japan origin, CFTR-dele16-17a-17b was detected in 24 alleles, the other variants were novel or very rare, and no pathogenic variants were detected in 8 alleles. In 22 CF alleles of Europe origin, F508del was detected in 11 alleles. In summary, clinical phenotype of Japanese CF patients is similar to European patients, but the prognosis is worse. The spectrum of CFTR variants in Japanese CF alleles is entirely different from that in European CF alleles.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

References

  1. O’Sullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009;373:1891–904.

    PubMed  Google Scholar 

  2. Ioannou L, McClaren BJ, Massie J, Lewis S, Metcalfe SA, Forrest L, et al. Population-based carrier screening for cystic fibrosis: A systematic review of 23 years of research. Genet Med. 2014;16:207–16.

    CAS  PubMed  Google Scholar 

  3. Naruse S, Ishiguro H, Yamamoto A, Kondo S, Nakakuki M, Hoshino M, et al. Incidence and exocrine pancreatic function of cystic fibrosis in Japan [abstract]. Pancreas. 2014;8:1395.

    Google Scholar 

  4. Shi R, Wang X, Lu X, Zhu Z, Xu Q, Wang H, et al. A systematic review of the clinical and genetic characteristics of Chinese patients with cystic fibrosis. Pediatr Pulmonol. 2020;55:3005–11.

    Google Scholar 

  5. Sohn YB, Ko JM, Jang JY, Seong MW, Park SS, Suh DI, et al. Deletion of exons 16-17b of CFTR is frequently identified in Korean patients with cystic fibrosis. Eur J Med Genet. 2019;62:103681.

    PubMed  Google Scholar 

  6. Liu LC, Shyur SD, Chu SH, Huang LH, Kao YH, Lei WT, et al. Cystic fibrosis: Experience in one institution. J Microbiol Immunol Infect. 2014;47:358–61.

    PubMed  Google Scholar 

  7. Fujiki K, Ishiguro H, Ko SB, Mizuno N, Suzuki Y, Takemura T, et al. Genetic evidence for CFTR dysfunction in Japanese: background for chronic pancreatitis. J Med Genet. 2004;41:e55.

    CAS  PubMed Central  Google Scholar 

  8. Kondo S, Fujiki K, Ko SB, Yamamoto A, Nakakuki M, Ito Y, et al. Functional characteristics of L1156F-CFTR associated with alcoholic chronic pancreatitis in Japanese. Am J Physiol Gastrointest Liver Physiol. 2015;309:G260–9.

    CAS  PubMed Central  Google Scholar 

  9. Sakamoto H, Yajima T, Suzuki K, Ogawa Y. Cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation associated with a congenital bilateral absence of vas deferens. Int J Urol. 2008;15:270–1.

    PubMed  Google Scholar 

  10. Lee JH, Choi JH, Namkung W, Hanrahan JW, Chang J, Song SY, et al. A haplotype-based molecular analysis of CFTR mutations associated with respiratory and pancreatic diseases. Hum Mol Genet. 2003;12:2321–32.

    CAS  PubMed  Google Scholar 

  11. Wang P, Naruse S, Yin H, Yu Z, Zhuang T, Ding W, et al. The susceptibility of T5-TG12 of the CFTR gene in chronic bronchitis occurrence in a Chinese population in Jiangsu province, China. J Biomed Res. 2012;26:410–7.

    PubMed  PubMed Central  Google Scholar 

  12. McCormick J, Ogston SA, Sims EJ, Mehta A. Asians with cystic fibrosis in the UK have worse disease outcomes than clinic matched white homozygous delta F508 controls. J Cyst Fibros. 2005;4:53–8.

    PubMed  Google Scholar 

  13. Bosch B, Bilton D, Sosnay P, Raraigh KS, Mak DYF, Ishiguro H, et al. Ethnicity impacts the cystic fibrosis diagnosis: A note of caution. J Cyst Fibros. 2017;16:488–91.

    PubMed  Google Scholar 

  14. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell. 1993;73:1251–4.

    CAS  PubMed  Google Scholar 

  15. Ferec C, Cutting GR. Assessing the disease-liability of mutations in CFTR. Cold Spring Harb Perspect Med. 2012;2:a009480.

    PubMed  PubMed Central  Google Scholar 

  16. Izumikawa K, Tomiyama Y, Ishimoto H, Sakamoto N, Imamura Y, Seki M, et al. Unique mutations of the cystic fibrosis transmembrane conductance regulator gene of three cases of cystic fibrosis in Nagasaki, Japan. Intern Med. 2009;48:1327–31.

    PubMed  Google Scholar 

  17. Nakakuki M, Fujiki K, Yamamoto A, Ko SB, Yi L, Ishiguro M, et al. Detection of a large heterozygous deletion and a splicing defect in the CFTR transcripts from nasal swab of a Japanese case of cystic fibrosis. J Hum Genet. 2012;57:427–33.

    CAS  Google Scholar 

  18. Liu K, Xu W, Xiao M, Zhao X, Bian C, Zhang Q, et al. Characterization of clinical and genetic spectrum of Chinese patients with cystic fibrosis. Orphanet J Rare Dis. 2020;15:150.

    PubMed Central  Google Scholar 

  19. Naruse S, Ishiguro H, Suzuki Y, Fujiki K, Ko SB, Mizuno N, et al. A finger sweat chloride test for the detection of a high-risk group of chronic pancreatitis. Pancreas. 2004;28:e80–5.

    PubMed  Google Scholar 

  20. Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011;10:S29–36.

    PubMed  Google Scholar 

  21. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: The global lung function 2012 equations. Eur Respir J. 2012;40:1324–43.

    PubMed  PubMed Central  Google Scholar 

  22. Mushtaq MU, Gull S, Mushtaq K, Abdullah HM, Khurshid U, Shahid U, et al. Height, weight, and BMI percentiles and nutritional status relative to the international growth references among Pakistani school-aged children. BMC Pediatr. 2012;12:31.

    PubMed Central  Google Scholar 

  23. Boëlle PY, Debray D, Guillot L, Clement A, Corvol H, French CF. Modifier gene study investigators. Cystic fibrosis liver disease: Outcomes and risk factors in a large cohort of French patients. Hepatology. 2019;69:1648–56.

    PubMed  Google Scholar 

  24. Kawase M, Ogawa M, Hoshina T, Kojiro M, Nakakuki M, Naruse S, et al. Japanese siblings of cystic fibrosis with a novel large heterozygous deletion in the CFTR gene. Front Pediatr. 2022;9:800095.

    PubMed  PubMed Central  Google Scholar 

  25. Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, et al. Diagnosis of cystic fibrosis: Consensus guidelines from the cystic fibrosis foundation. J Pediatr. 2017;181S:S4–15.

    Google Scholar 

  26. Sosnay PR, White TB, Farrell PM, Ren CL, Derichs N, Howenstine MS, et al. Diagnosis of cystic fibrosis in nonscreened populations. J Pediatr. 2017;181S:S52–7.

    PubMed  Google Scholar 

  27. Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397:2195–211.

  28. Bombieri C, Claustres M, De Boeck K, Derichs N, Dodge J, Girodon E, et al. Recommendations for the classification of diseases as CFTR-related disorders. J Cyst Fibros. 2011;10:S86–102.

    CAS  PubMed  Google Scholar 

  29. Palomaki GE, FitzSimmons SC, Haddow JE. Clinical sensitivity of prenatal screening for cystic fibrosis via CFTR carrier testing in a United States panethnic population. Genet Med. 2004;6:405–14.

    PubMed  Google Scholar 

  30. Imaizumi Y. Incidence and mortality rates of cystic fibrosis in Japan, 1969-1992. Am J Med Genet. 1995;58:161–8.

    CAS  Google Scholar 

  31. Deignan JL, Astbury C, Cutting GR, Del Gaudio D, Gregg AR, Grody WW, et al. CFTR variant testing: a technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2020;22:1288–95.

    PubMed  PubMed Central  Google Scholar 

  32. Quinton PM. What is good about cystic fibrosis? Curr Biol. 1994;4:742–3.

    CAS  PubMed  Google Scholar 

  33. Kintu B, Brightwell A. Episodic seasonal Pseudo-Bartter syndrome in cystic fibrosis. Paediatr Respir Rev. 2014;15:19–21.

    Google Scholar 

  34. Pique L, Graham S, Pearl M, Kharrazi M, Schrijver I. Cystic fibrosis newborn screening programs: implications of the CFTR variant spectrum in nonwhite patients. Genet Med. 2017;19:36–44.

    PubMed  Google Scholar 

  35. Schrijver I, Pique L, Graham S, Pearl M, Cherry A, Kharrazi M. The Spectrum of CFTR variants in nonwhite cystic fibrosis patients: Implications for molecular diagnostic testing. J Mol Diagn. 2016;18:39–50.

    CAS  PubMed  Google Scholar 

  36. Sheridan MB, Hefferon TW, Wang N, Merlo C, Milla C, Borowitz D, et al. CFTR transcription defects in pancreatic sufficient cystic fibrosis patients with only one mutation in the coding region of CFTR. J Med Genet. 2011;48:235–41.

    CAS  PubMed  Google Scholar 

  37. Wakabayashi-Nakao K, Yu Y, Nakakuki M, Hwang TC, Ishiguro H, Sohma Y. Characterization of Δ(G970-T1122)-CFTR, the most frequent CFTR mutant identified in Japanese cystic fibrosis patients. J Physiol Sci. 2019;69:103–12.

    CAS  PubMed  Google Scholar 

  38. Gee HY, Kim CK, Kim SW, Lee JH, Kim JH, Kim KH, et al. The L441P mutation of cystic fibrosis transmembrane conductance regulator and its molecular pathogenic mechanisms in a Korean patient with cystic fibrosis. J Korean Med Sci. 2010;25:166–71.

    PubMed  Google Scholar 

  39. Loo TW, Bartlett MC, Wang Y, Clarke DM. The chemical chaperone CFcor-325 repairs folding defects in the transmembrane domains of CFTR-processing mutants. Biochem J. 2006;395:537–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  40. Clain J, Fritsch J, Lehmann-Che J, Bali M, Arous N, Goossens M, et al. Two mild cystic fibrosis-associated mutations result in severe cystic fibrosis when combined in cis and reveal a residue important for cystic fibrosis transmembrane conductance regulator processing and function. J Biol Chem. 2001;276:9045–9.

    CAS  PubMed  Google Scholar 

  41. Fanen P, Labarthe R, Garnier F, Benharouga M, Goossens M, Edelman A. Cystic fibrosis phenotype associated with pancreatic insufficiency does not always reflect the cAMP-dependent chloride conductive pathway defect. Analysis of C225R-CFTR and R1066C-CFTR. J Biol Chem. 1997;272:30563–6.

    CAS  PubMed  Google Scholar 

  42. DeStefano S, Gees M, Hwang TC. Physiological and pharmacological characterization of the N1303K mutant CFTR. J Cyst Fibros. 2018;17:573–81.

    CAS  PubMed Central  Google Scholar 

Download references

Acknowledgements

We thank Drs. Ito S, Ichinoi N, Wada Y, Sakamoto O, Sanada Y, Harada Y, Shoji S, Hoshikawa Y, Kanda K, Kando N, Shimizu M, Ichihara T, Endo A, Mizuno Y, Obata M, Maruyama S, Baba Y, Yanagimoto K, Arai K, Kojima D, Sato Y, Itoh K, Takahara T, Harada T, Ishii H, Kushima H, Fukuda Y, Tanoue K, Kawakita R, Murakami Y, Asao T, Kitabayashi T, Azuma A, Usuki J, Koga H, Hagio Y, Fukasawa M, Fukaya S, Ito R, Abukawa D, Hoshi Y, Umetsu S, Ishii M, Kojiro M, Kawase M, Tabata K, Ito T, Arakaki Y, Yokoyama N, Mitani Y, Fukumori T, Ishikawa S, Wada T, Nagai Y, Shiona S, Sakata Y, Yamasaki K, Igata F, and Ishii H for providing clinical data of CF patients. We thank Dr. Stewart AK for English editing of the manuscript.

Funding

This work was supported by grants from the Japan Society for the Promotion of Science, the Japanese study group for pediatric rare and intractable hepato-biliary-pancreatic diseases provided by the Ministry of Health, Labour, and Welfare of Japan, and scholarship donations by Chugai Pharmaceutical Co. Ltd.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hiroshi Ishiguro.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kozawa, Y., Yamamoto, A., Nakakuki, M. et al. Clinical and genetic features of cystic fibrosis in Japan. J Hum Genet 68, 671–680 (2023). https://doi.org/10.1038/s10038-023-01160-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s10038-023-01160-2

Search

Quick links